Colossal Biosciences is reportedly valued at up to $30B but hasn't brought back a single extinct animal yet. So what are investors buying? — TFN

Colossal hasn’t revived a single extinct species, yet Colossal is reportedly in talks at a $20 billion to $30 billion valuation.

That would be up to triple the $10.2 billion it was worth in January 2025.

Its platform, spinouts, and speculative backing look like the real reason investors are interested.

Colossal Biosciences hasn’t brought back a single extinct animal. Not the woolly mammoth, not the dodo, not the Tasmanian tiger. And yet the company is reportedly in talks to raise fresh capital at a valuation of $20 billion to $30 billion, according to Axios.

If the round lands at the top of that range, it would nearly triple the $10.2 billion valuation it carried when Tech Funding News covered its $200 million Series C in January 2025, roughly sixteen months ago.